◎ Sugi Atlas

Atlas / Gene / CYP4F2

CYP4F2

gene
On this page

Summary

CYP4F2 (cytochrome P450 family 4 subfamily F member 2, HGNC:2645) is a protein-coding gene on chromosome 19p13.12, encoding Cytochrome P450 4F2 (P78329). A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, eicosanoids and vitamins.

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. The enzyme starts the process of inactivating and degrading leukotriene B4, a potent mediator of inflammation. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Another member of this family, CYP4F11, is approximately 16 kb away.

Source: NCBI Gene 8529 — RefSeq curated summary.

At a glance

  • GWAS associations: 21
  • Clinical variants (ClinVar): 109 total
  • Druggable target: yes — 2 molecules with ChEMBL bioactivity
  • MANE Select transcript: NM_001082

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:2645
Approved symbolCYP4F2
Namecytochrome P450 family 4 subfamily F member 2
Location19p13.12
Locus typegene with protein product
StatusApproved
Ensembl geneENSG00000186115
Ensembl biotypeprotein_coding
OMIM604426
Entrez8529

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 19 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000011989, ENST00000221700, ENST00000392846, ENST00000586927, ENST00000587671, ENST00000589654, ENST00000592710, ENST00000608168, ENST00000886781, ENST00000886782, ENST00000886783, ENST00000886784, ENST00000886785, ENST00000886786, ENST00000886787, ENST00000886788, ENST00000886789, ENST00000886790, ENST00000886791, ENST00000886792, ENST00000886793, ENST00000886794, ENST00000965125

RefSeq mRNA: 1 — MANE Select: NM_001082 NM_001082

CCDS: CCDS12336

Canonical transcript exons

ENST00000221700 — 13 exons

ExonStartEnd
ENSE000013477511589802615898074
ENSE000016664991587802315878936
ENSE000034826021587976415879897
ENSE000035012621589031215890433
ENSE000035071721588592415886053
ENSE000035299091588942315889693
ENSE000035897641588624215886308
ENSE000036252901587960415879668
ENSE000036344311587934615879428
ENSE000036375851589550615895650
ENSE000037064001589741415897612
ENSE000037256311589252915892582
ENSE000037280111589230915892436

Expression profiles

Bgee: expression breadth ubiquitous, 148 present calls, max score 98.04.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.2797 / max 518.1381, expressed in 60 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter IDTPM avgSamples expressed
1797731.279760

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
jejunal mucosaUBERON:000039998.04gold quality
right lobe of liverUBERON:000111497.84gold quality
liverUBERON:000210796.42gold quality
ileal mucosaUBERON:000033195.83gold quality
duodenumUBERON:000211493.48gold quality
corpus epididymisUBERON:000435992.92gold quality
nephron tubuleUBERON:000123191.88gold quality
kidney epitheliumUBERON:000481989.50gold quality
renal glomerulusUBERON:000007486.88gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099186.19gold quality
pancreatic ductal cellCL:000207985.82silver quality
mucosa of transverse colonUBERON:000499185.82gold quality
metanephric glomerulusUBERON:000473685.72gold quality
upper arm skinUBERON:000426383.47silver quality
small intestineUBERON:000210882.98gold quality
small intestine Peyer’s patchUBERON:000345482.64gold quality
male germ line stem cell (sensu Vertebrata) in testisCL:0000089 ∩ UBERON:000047380.46gold quality
adult mammalian kidneyUBERON:000008280.19gold quality
adult organismUBERON:000702379.29gold quality
kidneyUBERON:000211377.78gold quality
bone marrowUBERON:000237176.66gold quality
hair follicleUBERON:000207376.31gold quality
jejunumUBERON:000211575.02gold quality
gall bladderUBERON:000211074.56gold quality
cortex of kidneyUBERON:000122573.77gold quality
caput epididymisUBERON:000435873.66gold quality
mammalian vulvaUBERON:000099772.86silver quality
epithelium of esophagusUBERON:000197671.65silver quality
upper leg skinUBERON:000426270.90silver quality
bloodUBERON:000017870.58gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

ExperimentMarker?Max mean expression
E-ANND-3no0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): PPARA, RARA, SREBF1, SREBF2

miRNA regulators (miRDB)

36 targeting CYP4F2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-4795-3P100.0074.624024
HSA-MIR-126-5P100.0072.713180
HSA-MIR-450099.9972.722367
HSA-LET-7A-5P99.9872.291790
HSA-LET-7B-5P99.9872.311790
HSA-LET-7C-5P99.9872.291790
HSA-LET-7E-5P99.9872.291790
HSA-LET-7F-5P99.9872.561784
HSA-LET-7G-5P99.9872.371784
HSA-LET-7I-5P99.9872.371788
HSA-MIR-98-5P99.9872.331787
HSA-LET-7D-5P99.9671.761632
HSA-MIR-445899.9671.641650
HSA-MIR-128-3P99.9571.172484
HSA-MIR-216A-3P99.9571.192505
HSA-MIR-57799.7869.132479
HSA-MIR-129999.7771.242389
HSA-MIR-1296-3P99.7264.04636
HSA-MIR-875-3P99.6369.472548
HSA-MIR-56799.6368.571219
HSA-MIR-239299.4367.50708
HSA-MIR-889-5P99.4168.751025
HSA-MIR-29799.4069.581418
HSA-MIR-431899.3866.941505
HSA-MIR-797499.2465.481137
HSA-MIR-452-3P99.0166.251241
HSA-MIR-4520-3P98.7566.55963
HSA-MIR-450198.7267.19921
HSA-MIR-6830-3P98.6268.071760
HSA-MIR-449098.5168.47943

Literature-anchored findings (GeneRIF, showing 40)

  • CYP4F2 transcription and that CYP4F2 induction by statins is mediated by SREBP-2. (PMID:17142457)
  • CYP4F2-mediated tocopherol-omega-hydroxylation is a central feature underlying the different biological half-lives, and therefore biopotencies, of the tocopherols and tocotrienols (PMID:17284776)
  • identification of a functional variant in the CYP4F2 gene that alters the production of 20-HETE (PMID:17341693)
  • 3-hydroxystearate and 3-hydroxypalmitate are converted to omega-hydroxylated 3-OHDCA precursors in liver; CYP4F11 and, to a lesser extent, CYP4F2 catalyzed omega-hydroxylation of 3-hydroxystearate; CYP4F3b, CYP4F12, and CYP4A11 had negligible activity. (PMID:18065749)
  • a functional variant of the CYP4F2 regulatory region, which increases the binding affinity of NF-kappaB, increases the risk for hypertension (PMID:18235092)
  • Genetic variation of CYP4F2 was associated with a clinically relevant effect on warfarin requirement. (PMID:18250228)
  • In humans that polymorphisms of the CYP4F2 and CYP4A11 genes have opposite effects on 20-hydroxyeicosatetraenoic acid excretion. (PMID:18391101)
  • A common CYP4F2 V433M polymorphism might increase the risk of incident ischemic stroke in male subjects only partially through its elevating effect on BP. (PMID:18574070)
  • analysis of the expression of CYP4F2 in human liver and kidney (PMID:18662666)
  • A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. (PMID:18787519)
  • rs1558139 might be a genetic marker for essential hypertension and the T-T-G haplotype might be a protective genetic marker for it in Japanese men (PMID:18971550)
  • Polymorphism of CYP4F2 gene is associated with myocardial infarction in Japanese men. (PMID:19097922)
  • A relevant role for CYP4F2 V433M polymorphism in the pharmacogenetics of coumarin anticoagulants. (PMID:19270263)
  • In the kidney of transgenic mice, human recombinant CYP4F2 was localized to renal proximal tubule epithelia and was expressed at a higher level than in control mice, leading to increased urinary 20-HETE excretion. (PMID:19279555)
  • warfarin dose variance is explained by single nucleotide polymorphisms in VKORC1, CYP2C9, and CYP4F2 (PMID:19300499)
  • Data from the present results indicated that MI was associated with G allele of rs2108622 in men, suggesting that T-C-G haplotype might serve as genetic marker for Myocardial Infarction in men. (PMID:19957603)
  • Association of common variants of CYP4F2 with stroke in male Han Chinese population is reported. (PMID:20130494)
  • CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. (PMID:20227456)
  • Significant associations with warfarin dose were seen for VKORC1 -1639, CYP2C9*2 and *3, the CYP4F2 SNP, and VKORC1 3730 (PMID:20499136)
  • four genetic polymorphisms known to influence warfarin dosing (VKORC1 rs9923231, CYP2C9 rs1799853, CYP2C9 rs1057910 and CYP4F2 rs2108622) (PMID:20555338)
  • Two common SNPs in CYP4F2 gene cause significant alterations in vitamin E-omega-hydroxylase specific activity using six dietary tocopherols and tocotrienols and arachidonic acid as substrates. (PMID:20861217)
  • Phenprocoumon maintenance dosage depended on polymorphisms in the VKORC1 gene. CYP2C9 and CYP4F2 were of modest relevance. (PMID:21063236)
  • Results indicate that pharmacogenetic testing for VKORC1*2, CYP2C9*2 and CYP2C9*3 polymorphisms is more informative regarding warfarin dose requirements than testing for VKORC1*3, VKORC1*4, and CYP4F2 (1347 C > T) polymorphisms. (PMID:21127708)
  • The CYP4F2 V433M polymorphism is associated with the size of arterial wave reflections in male Chinese, or individuals with a faster pulse rate. (PMID:21150635)
  • limited (to population groups) effect of genetic variants on maintenance warfarin dose in a multi-ethnic Asian population (PMID:21475774)
  • Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses. (PMID:21562135)
  • 1347A allele of CYP4F2 gene is an important risk factor for hypertension and ischemic stroke. (PMID:21625857)
  • Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione (PMID:21883387)
  • A novel CYP4F2 transgenic mouse model driven by the cyto-megalovirus (CMV) promoter was generated and identified by PCR and subsequent sequencing. (PMID:21887457)
  • Quantitative PCR assays for VKORC1, CYP4F2, GGCX and CALU identified two copies in all populations. (PMID:22188360)
  • The present study indicated that VKORC1, CYP4F2, and CYP2C9 genotypes and interacting drugs had a significant impact on the warfarin maintenance dose in Chinese patients with heart valve replacement (PMID:22198820)
  • Approximately one fourth of Tibetans had the mutant T-allele of CYP4F2 rs108622 (PMID:22393834)
  • The researchers evaluated the prevalence of the CYP4F2 polymorphism in a population of Omanis. (PMID:22452429)
  • The initial positive association of the CYP4F2 V433M polymorphism with components of metabolic syndrome and MetS itself, found in MDC-CVA, was partially denied in another large cohort. (PMID:22484021)
  • The multiple linear regression model including VKORC1-1639G>A, CYP2C9, CYP4F2 and clinical factors (body surface area (BSA) and age) could explain 42 % of the variance in the warfarin maintenance dose. (PMID:22528326)
  • Report algorithm predicting warfarin dose in Chinese Han patients with valvular atrial fibrillation based on CYP4F2/CYP2C9/VKORC1 polymorphisms. (PMID:22534826)
  • Dose variability in CYP4F2 genotypes is attributable to both warfarin clearance and sensitivity differences in Korean patients with mechanical heart valves. (PMID:22549502)
  • Functional polymorphisms in CYP2C9, CYP4F2 and VKORC1 genes affect response to warfarin dose in an admixed Omani patient cohort. (PMID:22854539)
  • CYP4F2 genetic variation did not affect the pharmacokinetics and pharmacodynamics of low-dose warfarin. (PMID:22855348)
  • Found the frequency of the CYP4F2 rs2108622 C allele in individuals with implanted mechanical valve prostheses was 79.5% and T-allele frequency was 20.5%.TT-homozygous individuals required a 0.56 mg/day higher dose of warfarin than their CC counterparts. (PMID:23013706)

Cross-species orthologs

36 orthologs

OrganismSymbolGene ID
danio_reriocyp4t8ENSDARG00000004964
danio_reriocyp4f3ENSDARG00000053530
mus_musculusCyp4f14ENSMUSG00000024292
mus_musculusCyp4f15ENSMUSG00000073424
mus_musculusCyp4f40ENSMUSG00000090700
rattus_norvegicusCyp4f1ENSRNOG00000004786
rattus_norvegicusCyp4f4ENSRNOG00000032895
rattus_norvegicusCyp4f40ENSRNOG00000043344
drosophila_melanogasterCyp4d1FBGN0005670
drosophila_melanogasterCyp4d2FBGN0011576
drosophila_melanogasterCyp4e2FBGN0014469
drosophila_melanogasterCyp4c3FBGN0015032
drosophila_melanogasterCyp4d8FBGN0015033
drosophila_melanogasterCyp4e1FBGN0015034
drosophila_melanogasterCyp4e3FBGN0015035
drosophila_melanogasterCyp4ae1FBGN0015036
drosophila_melanogasterCyp4p1FBGN0015037
drosophila_melanogasterCyp4d14FBGN0023541
drosophila_melanogasterCyp4s3FBGN0030615
drosophila_melanogasterCyp4ac1FBGN0031693
drosophila_melanogasterCyp4ac2FBGN0031694
drosophila_melanogasterCyp4ac3FBGN0031695
drosophila_melanogasterCyp4d21FBGN0031925
drosophila_melanogasterCyp4ad1FBGN0033292
drosophila_melanogasterCyp4p2FBGN0033395
drosophila_melanogasterCyp4p3FBGN0033397
drosophila_melanogasterCyp4aa1FBGN0034053
drosophila_melanogasterCyp4d20FBGN0035344
drosophila_melanogasterCyp312a1FBGN0036778
caenorhabditis_elegansWBGENE00007140
caenorhabditis_elegansWBGENE00009226
caenorhabditis_elegansWBGENE00010354
caenorhabditis_elegansWBGENE00013381
caenorhabditis_elegansWBGENE00016147
caenorhabditis_elegansWBGENE00021200
caenorhabditis_elegansWBGENE00021412

Paralogs (12): CYP19A1 (ENSG00000137869), CYP4B1 (ENSG00000142973), CYP4V2 (ENSG00000145476), CYP4A22 (ENSG00000162365), CYP4F11 (ENSG00000171903), CYP4F22 (ENSG00000171954), CYP4Z1 (ENSG00000186160), CYP4F12 (ENSG00000186204), CYP4X1 (ENSG00000186377), CYP4F8 (ENSG00000186526), CYP4F3 (ENSG00000186529), CYP4A11 (ENSG00000187048)

Protein

Protein identifiers

Cytochrome P450 4F2 — P78329 (reviewed: P78329)

Alternative names: 20-hydroxyeicosatetraenoic acid synthase, Arachidonic acid omega-hydroxylase, CYPIVF2, Cytochrome P450-LTB-omega, Docosahexaenoic acid omega-hydroxylase, Leukotriene-B(4) 20-monooxygenase 1, Leukotriene-B(4) omega-hydroxylase 1, Phylloquinone omega-hydroxylase CYP4F2

All UniProt accessions (5): A0A0A0MQR0, P78329, K7EK90, K7EPM0, K7EQI8

UniProt curated annotations — full annotation on UniProt →

Function. A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, eicosanoids and vitamins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of long- and very long-chain fatty acids. Displays high omega-hydroxylase activity toward polyunsaturated fatty acids (PUFAs). Participates in the conversion of arachidonic acid to omega-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure. Plays a role in the oxidative inactivation of eicosanoids, including both pro-inflammatory and anti-inflammatory mediators such as leukotriene B4 (LTB4), lipoxin A4 (LXA4), and several HETEs. Catalyzes omega-hydroxylation of 3-hydroxy fatty acids. Converts monoepoxides of linoleic acid leukotoxin and isoleukotoxin to omega-hydroxylated metabolites. Contributes to the degradation of very long-chain fatty acids (VLCFAs) by catalyzing successive omega-oxidations and chain shortening. Plays an important role in vitamin metabolism by chain shortening. Catalyzes omega-hydroxylation of the phytyl chain of tocopherols (forms of vitamin E), with preference for gamma-tocopherols over alpha-tocopherols, thus promoting retention of alpha-tocopherols in tissues. Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation.

Subcellular location. Microsome membrane. Endoplasmic reticulum membrane.

Tissue specificity. Liver. Also present in kidney: specifically expressed in the S2 and S3 segments of proximal tubules in cortex and outer medulla.

Disease relevance. Coumarin resistance (CMRES) [MIM:122700] A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti-coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. Disease susceptibility may be associated with variants affecting the gene represented in this entry. The variant Met-433 is associated with coumarin (the brand name of warfarin) resistance by increasing coumarin maintenance dose in patients on this anti-coagulant therapy. This is probably due to decreased activity of the phylloquinone omega-hydroxylase activity, leading to an increase in hepatic vitamin K levels that warfarin must antagonize.

Activity regulation. Inhibited by dietary sesamin.

Pathway. Lipid metabolism; arachidonate metabolism. Lipid metabolism; leukotriene B4 degradation. Cofactor degradation; phylloquinone degradation.

Similarity. Belongs to the cytochrome P450 family.

Isoforms (2)

UniProt IDNamesCanonical?
P78329-11yes
P78329-22

RefSeq proteins (1): NP_001073* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR001128Cyt_P450Family
IPR002401Cyt_P450_E_grp-IFamily
IPR017972Cyt_P450_CSConserved_site
IPR036396Cyt_P450_sfHomologous_superfamily
IPR050196Cytochrome_P450_MonooxFamily

Pfam: PF00067

Enzyme classification (BRENDA):

  • EC 1.14.14.94 — leukotriene-B4 20-monooxygenase (BRENDA: 4 organisms, 65 substrates, 15 inhibitors, 41 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

15 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

SubstrateKm (mM)Measurements
LEUKOTRIENE B40.0002–0.86815
6-TRANS-LEUKOTRIENE B40.0556–0.09613
Z12(13)-EPOXYOCTADEC-Z9-ENOIC ACID0.0618–0.1353
Z9(10)-EPOXYOCTADEC-Z12-ENOIC ACID0.0466–0.16313
Z9(10)-EPOXYOCTADECANOIC ACID0.0063–0.03573
12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID0.0142–0.07522
12-HYDROXYSTEARATE0.0409–0.04232
LIPOXIN A40.0582–0.2542
NADPH0.0008–0.0012
20-HYDROXY-LEUKOTRIENE B40.00651
5-DEOXY-LEUKOTRIENE B40.00561
5-EPI-LEUKOTRIENE B40.00661
6-TRANS-12-EPI-LEUKOTRIENE B40.00381
LIPOXIN B40.01791
PROSTAGLANDIN A10.041

Catalyzed reactions (Rhea), 12 shown:

  • an organic molecule + reduced [NADPH–hemoprotein reductase] + O2 = an alcohol + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:17149)
  • leukotriene B4 + reduced [NADPH–hemoprotein reductase] + O2 = 20-hydroxy-leukotriene B4 + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:22176)
  • 22-oxodocosanoate + reduced [NADPH–hemoprotein reductase] + O2 = docosanedioate + oxidized [NADPH–hemoprotein reductase] + H2O + 2 H(+) (RHEA:39043)
  • 26-oxohexacosanoate + reduced [NADPH–hemoprotein reductase] + O2 = hexacosanedioate + oxidized [NADPH–hemoprotein reductase] + H2O + 2 H(+) (RHEA:39047)
  • 22-hydroxydocosanoate + reduced [NADPH–hemoprotein reductase] + O2 = 22-oxodocosanoate + oxidized [NADPH–hemoprotein reductase] + 2 H2O + H(+) (RHEA:39055)
  • 26-hydroxyhexacosanoate + reduced [NADPH–hemoprotein reductase] + O2 = 26-oxohexacosanoate + oxidized [NADPH–hemoprotein reductase] + 2 H2O + H(+) (RHEA:39059)
  • tetracosanoate + reduced [NADPH–hemoprotein reductase] + O2 = 24-hydroxytetracosanoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:39719)
  • 3-hydroxyhexadecanoate + reduced [NADPH–hemoprotein reductase] + O2 = 3,16-dihydroxyhexadecanoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:39731)
  • 3-hydroxyoctadecanoate + reduced [NADPH–hemoprotein reductase] + O2 = 3,18-dihydroxyoctadecanoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:39735)
  • (5Z,8Z,11Z,14Z)-eicosatetraenoate + reduced [NADPH–hemoprotein reductase] + O2 = 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:39755)
  • (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + reduced [NADPH–hemoprotein reductase] + O2 = 20-hydroxy-(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:39791)
  • docosanoate + reduced [NADPH–hemoprotein reductase] + O2 = 22-hydroxydocosanoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:40079)

UniProt features (18 total): sequence variant 6, sequence conflict 5, splice variant 3, binding site 2, propeptide 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-P78329-F191.970.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 328 (covalent); 468 (axial binding residue)

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

IDPathway
R-HSA-211935Fatty acids
R-HSA-211958Miscellaneous substrates
R-HSA-211979Eicosanoids
R-HSA-2142691Synthesis of Leukotrienes (LT) and Eoxins (EX)
R-HSA-2142816Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)

MSigDB gene sets: 218 (showing top): BROWNE_HCMV_INFECTION_30MIN_DN, GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GOBP_LIPID_MODIFICATION, GOBP_FATTY_ACID_CATABOLIC_PROCESS, REACTOME_BIOLOGICAL_OXIDATIONS, GOBP_REGULATION_OF_ICOSANOID_SECRETION, GOBP_REGULATION_OF_BLOOD_PRESSURE, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_REGULATION_OF_ORGANIC_ACID_TRANSPORT, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GNF2_GSTM1, GOBP_RENAL_SYSTEM_PROCESS_INVOLVED_IN_REGULATION_OF_BLOOD_VOLUME, GNF2_HPN, GOBP_REGULATION_OF_SYSTEMIC_ARTERIAL_BLOOD_PRESSURE

GO Biological Process (23): very long-chain fatty acid metabolic process (GO:0000038), long-chain fatty acid metabolic process (GO:0001676), renal water homeostasis (GO:0003091), pressure natriuresis (GO:0003095), icosanoid metabolic process (GO:0006690), leukotriene metabolic process (GO:0006691), xenobiotic metabolic process (GO:0006805), blood coagulation (GO:0007596), regulation of blood pressure (GO:0008217), fatty acid omega-oxidation (GO:0010430), arachidonate metabolic process (GO:0019369), epoxygenase P450 pathway (GO:0019373), negative regulation of icosanoid secretion (GO:0032304), positive regulation of icosanoid secretion (GO:0032305), leukotriene B4 catabolic process (GO:0036101), vitamin E metabolic process (GO:0042360), menaquinone catabolic process (GO:0042361), phylloquinone catabolic process (GO:0042376), vitamin K catabolic process (GO:0042377), sodium ion homeostasis (GO:0055078), omega-hydroxylase P450 pathway (GO:0097267), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631)

GO Molecular Function (17): monooxygenase activity (GO:0004497), iron ion binding (GO:0005506), arachidonate epoxygenase activity (GO:0008392), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen (GO:0016709), alkane 1-monooxygenase activity (GO:0018685), heme binding (GO:0020037), leukotriene-B4 20-monooxygenase activity (GO:0050051), arachidonate omega-hydroxylase activity (GO:0052869), alpha-tocopherol omega-hydroxylase activity (GO:0052871), 20-hydroxy-leukotriene B4 omega oxidase activity (GO:0097258), 20-aldehyde-leukotriene B4 20-monooxygenase activity (GO:0097259), long-chain fatty acid omega-hydroxylase activity (GO:0102033), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712), metal ion binding (GO:0046872)

GO Cellular Component (6): cytoplasm (GO:0005737), endoplasmic reticulum membrane (GO:0005789), apical plasma membrane (GO:0016324), intracellular membrane-bounded organelle (GO:0043231), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

CategoryPathways
Cytochrome P450 - arranged by substrate type3
Arachidonate metabolism2

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
monooxygenase activity4
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen3
fatty acid metabolic process2
renal system process2
icosanoid metabolic process2
metabolic process2
regulation of icosanoid secretion2
icosanoid secretion2
ketone catabolic process2
oxidoreductase activity2
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen2
intracellular anatomical structure2
cellular anatomical structure2
multicellular organismal-level water homeostasis1
regulation of body fluid levels1
carboxylic acid metabolic process1
cellular response to xenobiotic stimulus1
hemostasis1
wound healing1
coagulation1
blood circulation1
regulation of biological quality1
fatty acid oxidation1
long-chain fatty acid metabolic process1
unsaturated fatty acid metabolic process1
olefinic compound metabolic process1
arachidonate metabolic process1
negative regulation of secretion1
negative regulation of fatty acid transport1
positive regulation of secretion1
positive regulation of fatty acid transport1
leukotriene catabolic process1
leukotriene B4 metabolic process1
long-chain fatty acid catabolic process1
icosanoid catabolic process1
menaquinone metabolic process1
vitamin K catabolic process1
fat-soluble vitamin catabolic process1
vitamin K metabolic process1
monoatomic cation homeostasis1

Protein interactions and networks

STRING

1812 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
CYP4F2VKORC1Q9BQB6967
CYP4F2GGCXP38435912
CYP4F2PPIGQ13427846
CYP4F2CALUO43852646
CYP4F2F7P08709631
CYP4F2CYP2C9P11712625
CYP4F2SLCO1B1Q9Y6L6625
CYP4F2TPMTP51580620
CYP4F2PROS1P07225611
CYP4F2NIPAL4Q0D2K0609
CYP4F2EPHX1P07099606
CYP4F2TTPAP49638592
CYP4F2NUDT15Q9NV35570
CYP4F2CYP1A2P05177560
CYP4F2DPYDQ12882558

IntAct

128 interactions, top by confidence:

ABTypeScore
CYP4F2CREB3psi-mi:“MI:0915”(physical association)0.560
CYP4F2SPAG4psi-mi:“MI:0915”(physical association)0.560
CYP4F2ZDHHC15psi-mi:“MI:0915”(physical association)0.560
CYP4F2ROM1psi-mi:“MI:0915”(physical association)0.560
CYP4F2TSPAN31psi-mi:“MI:0915”(physical association)0.560
CYP4F2HSD17B13psi-mi:“MI:0915”(physical association)0.560
CYP4F2TMEM51psi-mi:“MI:0915”(physical association)0.560
CYP4F2REEP2psi-mi:“MI:0915”(physical association)0.560
CYP4F2CPLX4psi-mi:“MI:0915”(physical association)0.560
CYP4F2RETREG3psi-mi:“MI:0915”(physical association)0.560
LEPROTL1CYP4F2psi-mi:“MI:0915”(physical association)0.560
CYP4F2FAM210Bpsi-mi:“MI:0915”(physical association)0.560
CYP4F2SCN3Bpsi-mi:“MI:0915”(physical association)0.560
CYP4F2PLEKHO1psi-mi:“MI:0915”(physical association)0.560
CYP4F2SLC2A13psi-mi:“MI:0915”(physical association)0.560

BioGRID (40): CREB3 (Two-hybrid), CYP4F2 (Affinity Capture-MS), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid), CYP4F2 (Two-hybrid)

ESM2 similar proteins: A0A087X1C5, E9Q816, O18992, O46658, P00191, P03940, P08686, P10633, P10634, P10635, P11714, P12394, P12938, P12939, P15540, P24456, P24457, P30437, P51589, P51590, P52786, P70085, P78329, Q01361, Q0IIF9, Q29473, Q29488, Q2LA59, Q2LA60, Q2LCM1, Q2XNC8, Q2XNC9, Q4V8D1, Q64403, Q64562, Q64680, Q6GUQ4, Q6VVW9, Q6VVX0, Q7Z449

Diamond homologs: A0A067DT54, A0A067E1K2, A0A0S2II38, A0A140JWM8, A0A1B4XBH8, A0A1W5T1Y6, A0A3Q7HBJ5, A0A517FNB9, A0A517FNC6, A0A5B8ND22, A0A9Y1LLN2, A0AAW1NEA3, A2QTE8, A2RRT9, A2Z212, A9QNE7, B0XZV0, B1NF18, B5BSX1, B6SSW8, B8AJL3, B8AV52, B8QHP1, B8QHP5, B9X287, F1SY66, G3XMC3, I1GQE7, K4CI52, L7T720, L7T8H2, O23051, O35728, O49858, O61387, O81077, O88833, P08682, P0DXH4, P14137

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 47 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

PathwayPartnersFoldFDR
FCGR3A-mediated phagocytosis536.0×8e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

109 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance68
Likely benign20
Benign12

Top pathogenic / likely-pathogenic (0)

SpliceAI

1796 predictions. Top by Δscore:

VariantEffectΔscore
19:15878935:TC:Tacceptor_gain1.0000
19:15878936:CC:Cacceptor_gain1.0000
19:15878936:CCTAG:Cacceptor_loss1.0000
19:15878937:C:CCacceptor_gain1.0000
19:15879340:CCTTA:Cdonor_loss1.0000
19:15879342:TTACC:Tdonor_loss1.0000
19:15879343:TAC:Tdonor_loss1.0000
19:15879344:A:ACdonor_gain1.0000
19:15879345:C:CCdonor_gain1.0000
19:15879345:C:CGdonor_loss1.0000
19:15879598:CCGCA:Cdonor_loss1.0000
19:15879599:CGCA:Cdonor_loss1.0000
19:15879600:GCAC:Gdonor_loss1.0000
19:15879601:CACCT:Cdonor_loss1.0000
19:15879602:ACCTC:Adonor_loss1.0000
19:15879603:CCTCA:Cdonor_loss1.0000
19:15879623:G:Cdonor_gain1.0000
19:15879667:GCCTG:Gacceptor_loss1.0000
19:15879670:T:Aacceptor_loss1.0000
19:15889419:CCA:Cdonor_loss1.0000
19:15889420:CACCT:Cdonor_loss1.0000
19:15889421:ACC:Adonor_loss1.0000
19:15890310:A:ACdonor_gain1.0000
19:15890311:C:CCdonor_gain1.0000
19:15878932:AGTTC:Aacceptor_gain0.9900
19:15878933:GTTC:Gacceptor_gain0.9900
19:15878934:TTC:Tacceptor_gain0.9900
19:15879343:TA:Tdonor_gain0.9900
19:15879388:T:Adonor_gain0.9900
19:15879429:CT:Cacceptor_loss0.9900

AlphaMissense

3438 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
19:15879360:G:CF461L0.992
19:15879360:G:TF461L0.992
19:15879362:A:GF461L0.992
19:15879849:G:CS388R0.987
19:15879849:G:TS388R0.987
19:15879851:T:GS388R0.987
19:15879408:A:CF445L0.983
19:15879408:A:TF445L0.983
19:15879410:A:GF445L0.983
19:15892369:G:CF155L0.982
19:15892369:G:TF155L0.982
19:15892371:A:GF155L0.982
19:15892391:C:GR148P0.981
19:15879618:A:GW434R0.980
19:15879618:A:TW434R0.980
19:15892392:G:TR148S0.979
19:15892404:A:GW144R0.978
19:15892404:A:TW144R0.978
19:15879369:A:CF458L0.977
19:15879369:A:TF458L0.977
19:15879371:A:GF458L0.977
19:15890427:A:GW178R0.975
19:15890427:A:TW178R0.975
19:15878915:G:CF473L0.972
19:15878915:G:TF473L0.972
19:15878917:A:GF473L0.972
19:15878936:C:AR466S0.970
19:15878936:C:GR466S0.970
19:15886024:A:GW339R0.970
19:15886024:A:TW339R0.970

dbSNP variants (sampled 300 via entrez): RS1000004278 (19:15885182 C>G), RS1000139809 (19:15885438 T>C,G), RS1000243500 (19:15879179 G>C), RS1000341178 (19:15899461 C>T), RS1000662363 (19:15900071 G>T), RS1000775989 (19:15899241 C>A,G), RS1000841993 (19:15896708 C>T), RS1000858698 (19:15891012 A>C,G), RS1000944570 (19:15895297 G>A), RS1001682680 (19:15894956 A>C), RS1001713734 (19:15894803 G>A), RS1002174112 (19:15891258 G>A,C), RS1002201556 (19:15895812 C>T), RS1002404950 (19:15884561 T>C,G), RS1002857923 (19:15893508 A>G)

Disease associations

OMIM: gene MIM:604426 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

21 associations (top):

StudyTraitp-value
GCST000360_3Warfarin maintenance dose3.000000e-10
GCST000436_3Acenocoumarol maintenance dosage3.000000e-10
GCST000792_2Warfarin maintenance dose3.000000e-08
GCST001142_2Vitamin E levels1.000000e-10
GCST001450_4Response to Vitamin E supplementation2.000000e-07
GCST001882_6Metabolite levels9.000000e-24
GCST002653_3Circulating phylloquinone levels3.000000e-07
GCST009733_117Urinary metabolite levels in chronic kidney disease2.000000e-18
GCST009733_118Urinary metabolite levels in chronic kidney disease2.000000e-15
GCST009733_135Urinary metabolite levels in chronic kidney disease3.000000e-12
GCST009733_70Urinary metabolite levels in chronic kidney disease4.000000e-20
GCST009735_18Urinary metabolite modules (eigenmetabolites) in chronic kidney disease6.000000e-20
GCST012020_162Serum metabolite levels1.000000e-15
GCST012020_525Serum metabolite levels6.000000e-26
GCST012020_526Serum metabolite levels6.000000e-17
GCST012021_66Serum metabolite levels6.000000e-26
GCST012021_67Serum metabolite levels6.000000e-17
GCST012021_87Serum metabolite levels1.000000e-15
GCST90011899_162Aspartate aminotransferase levels3.000000e-08
GCST90013663_15Alanine aminotransferase levels2.000000e-08
GCST90013664_41Aspartate aminotransferase levels6.000000e-08

EFO canonical traits (4, from GWAS)

EFO IDTrait name
EFO:0004725metabolite measurement
EFO:0004618vitamin K measurement
EFO:0005116urinary metabolite measurement
EFO:0004736aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3379 (SINGLE PROTEIN), CHEMBL4523986 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 90,901 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

MoleculeNamePhasePatents
CHEMBL157101KETOCONAZOLE475,361
CHEMBL477772PAZOPANIB415,540

PharmGKB: 1 entry (VIP=true, CPIC=true)

PharmGKB clinical annotations

12 annotations.

VariantTypeLevelDrugsPhenotypes
CYP4F21, CYP4F23Metabolism/PK3Vitamin K1
rs2108622Dosage1Awarfarin
rs2108622Dosage2AacenocoumarolAtrial Fibrillation
rs2108622Metabolism/PK3vitamin e
rs2108622Other3aspirin;clopidogrelAcute coronary syndrome
rs2108622Efficacy3warfarin
rs2108622Metabolism/PK3Vitamin K and analogues
rs2108622Dosage3phenprocoumon
rs2108622Other4warfarinover-anticoagulation
rs2108623Toxicity4anthracyclines and related substancesNeoplasms
rs2189784Dosage3warfarin
rs3093105Metabolism/PK3vitamin e

PharmGKB variants

14 variants.

VariantGenesLevelScore#Clin annotsDrugs
rs2108622CYP4F21A169.509Vitamin K and analogues;phenprocoumon;vitamin e;acenocoumarol;aspirin;clopidogrel;warfarin
rs2108623CYP4F24-1.001anthracyclines and related substances
rs2189784CYP4F232.751warfarin
rs3093105CYP4F230.001vitamin e
rs3093158CYP4F20.000
rs3093135CYP4F20.000
rs3093153CYP4F20.000
rs2074900CYP4F20.000
rs3093200CYP4F20.000
rs114396708CYP4F20.000
rs753169154CYP4F20.000
rs754533672CYP4F20.000
rs1292029455CYP4F20.000
rs550261161CYP4F20.000

PharmGKB dosing guidelines

1 guidelines.

SourceDrugGuidelineDosing?Recommendation?
CPICwarfarinAnnotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1yesyes

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CYP4 family

Most potent curated ligand interactions (4 total), top 4:

LigandActionAffinityParameter
HET0016Inhibition7.86pIC50
TP0472993Inhibition7.4pIC50
sesaminInhibition6.42pIC50
17-octadecynoic acidInhibition5.92pKi

Binding affinities (BindingDB)

116 measured of 117 human assays (117 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

LigandMeasureValuePatent
1,1,1-trifluoro-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propan-2-olIC5010 nMUS-11365192: Pyridine compound substituted with azole
3-[8-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]octyl]oxolane-3-carboxylic acidIC5014 nMUS-11365192: Pyridine compound substituted with azole
N-[[(2S)-oxolan-2-yl]methyl]-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propanamideIC5018 nMUS-11365192: Pyridine compound substituted with azole
1-acetyl-3-[8-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]octyl]pyrrolidine-3-carboxylic acidIC5018 nMUS-11365192: Pyridine compound substituted with azole
7-[[6-(4-chloro-1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]-3,4-dihydro-2H-chromene-2-carboxylic acidIC5020 nMUS-11365192: Pyridine compound substituted with azole
N-[[(2R)-oxolan-2-yl]methyl]-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propanamideIC5021 nMUS-11365192: Pyridine compound substituted with azole
N,N-dimethyl-2-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]cyclopropane-1-carboxamideIC5022 nMUS-11365192: Pyridine compound substituted with azole
3-hydroxy-N,N-dimethyl-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]cyclobutane-1-carboxamideIC5028 nMUS-11365192: Pyridine compound substituted with azole
7-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]-5,6,7,8-tetrahydronaphthalene-2-carboxylic acidIC5033 nMUS-11365192: Pyridine compound substituted with azole
N-[(2R)-2-methoxypropyl]-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propanamideIC5040 nMUS-11365192: Pyridine compound substituted with azole
2,2,2-trifluoro-1-[4-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]phenyl]ethanolIC5041 nMUS-11365192: Pyridine compound substituted with azole
2-[8-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]octyl]oxolane-2-carboxylic acidIC5043 nMUS-11365192: Pyridine compound substituted with azole
N-methyl-2-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propanamideIC5055 nMUS-11365192: Pyridine compound substituted with azole
trans-(1S,2S)-2-[2-fluoro-3-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC5058 nMUS-11365192: Pyridine compound substituted with azole
2-[2-fluoro-3-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC5060 nMUS-11365192: Pyridine compound substituted with azole
N-[(2S)-1-hydroxypropan-2-yl]-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propanamideIC5063 nMUS-11365192: Pyridine compound substituted with azole
N-[(2S)-2-hydroxypropyl]-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propanamideIC5073 nMUS-11365192: Pyridine compound substituted with azole
trans-(1R,2R)-2-[2-fluoro-3-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC5080 nMUS-11365192: Pyridine compound substituted with azole
(3R)-1-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]sulfonylpiperidine-3-carboxylic acidIC5086 nMUS-11365192: Pyridine compound substituted with azole
(2S)-2-[7-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]heptoxy]butanoic acidIC5090 nMUS-11365192: Pyridine compound substituted with azole
2-[3-fluoro-4-[2-[(6-pyrazolidin-3-yl-3-pyridinyl)oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC5091 nMUS-11365192: Pyridine compound substituted with azole
N-[(2R)-2-hydroxypropyl]-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propanamideIC5092 nMUS-11365192: Pyridine compound substituted with azole
3-[(3R)-3-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]piperidin-1-yl]sulfonylbenzoic acidIC5094 nMUS-11365192: Pyridine compound substituted with azole
3-[2-fluoro-5-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]-3-hydroxy-N,N-dimethylcyclobutane-1-carboxamideIC5099 nMUS-11365192: Pyridine compound substituted with azole
1,1-difluoro-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propan-2-olIC50100 nMUS-11365192: Pyridine compound substituted with azole
(2S)-7-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]-3,4-dihydro-2H-chromene-2-carboxylic acidIC50110 nMUS-11365192: Pyridine compound substituted with azole
N-[(2R)-1-hydroxypropan-2-yl]-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propanamideIC50120 nMUS-11365192: Pyridine compound substituted with azole
2-[2-fluoro-4-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC50120 nMUS-11365192: Pyridine compound substituted with azole
cis-(1R,2S)-2-[4-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC50120 nMUS-11365192: Pyridine compound substituted with azole
2-[2-fluoro-5-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC50130 nMUS-11365192: Pyridine compound substituted with azole
7-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]-3,4-dihydro-2H-chromene-2-carboxylic acidIC50140 nMUS-11365192: Pyridine compound substituted with azole
2-[7-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]heptoxy]butanoic acidIC50140 nMUS-11365192: Pyridine compound substituted with azole
(2S)-7-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]-3,4-dihydro-2H-chromene-2-carboxylic acidIC50160 nMUS-11365192: Pyridine compound substituted with azole
7-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]-1,2,3,4-tetrahydronaphthalene-2-carboxylic acidIC50170 nMUS-11365192: Pyridine compound substituted with azole
1-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]sulfonylpiperidine-3-carboxylic acidIC50180 nMUS-11365192: Pyridine compound substituted with azole
7-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]-3,4-dihydro-2H-chromene-2-carboxylic acidIC50190 nMUS-11365192: Pyridine compound substituted with azole
(2S)-7-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]-1,2,3,4-tetrahydronaphthalene-2-carboxylic acidIC50200 nMUS-11365192: Pyridine compound substituted with azole
2-[4-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC50200 nMUS-11365192: Pyridine compound substituted with azole
2-[7-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]heptoxy]propanoic acidIC50200 nMUS-11365192: Pyridine compound substituted with azole
(2R)-7-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]-1,2,3,4-tetrahydronaphthalene-2-carboxylic acidIC50240 nMUS-11365192: Pyridine compound substituted with azole
1-[3-oxo-3-[3-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]piperidin-1-yl]propyl]cyclopentane-1-carboxylic acidIC50260 nMUS-11365192: Pyridine compound substituted with azole
6-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]-3,4-dihydro-2H-chromene-3-carboxylic acidIC50260 nMUS-11365192: Pyridine compound substituted with azole
2-[2-fluoro-3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]cyclopropane-1-carboxylic acidIC50280 nMUS-11365192: Pyridine compound substituted with azole
1,1,1-trifluoro-2-[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenyl]propan-2-olIC50300 nMUS-11365192: Pyridine compound substituted with azole
3-fluoro-1-[4-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]pyridine-2-carbonyl]pyrrolidine-3-carboxylic acidIC50300 nMUS-11365192: Pyridine compound substituted with azole
(2R)-7-[(6-pyrazolidin-3-yl-3-pyridinyl)oxymethyl]-3,4-dihydro-2H-chromene-2-carboxylic acidIC50300 nMUS-11365192: Pyridine compound substituted with azole
(2R)-2-[7-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]heptoxy]butanoic acidIC50300 nMUS-11365192: Pyridine compound substituted with azole
(2R)-7-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]-3,4-dihydro-2H-chromene-2-carboxylic acidIC50310 nMUS-11365192: Pyridine compound substituted with azole
4-oxo-4-[(3R)-3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidin-1-yl]butane-1-sulfonamideIC50320 nMUS-11365192: Pyridine compound substituted with azole
2-[3-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]phenyl]cyclopropane-1-carboxylic acidIC50320 nMUS-11365192: Pyridine compound substituted with azole

ChEMBL bioactivities

430 potent at pChembl≥5 of 502 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
9.00ED501nMCHEMBL524809
8.52IC503nMCHEMBL5824435
8.52IC503nMCHEMBL5898405
8.46IC503.5nMCHEMBL5836266
8.36IC504.4nMCHEMBL5937636
8.29IC505.1nMCHEMBL5799100
8.29IC505.1nMCHEMBL5964770
8.24IC505.7nMCHEMBL5833066
8.21IC506.2nMCHEMBL5851671
8.19IC506.5nMCHEMBL5195099
8.19IC506.4nMCHEMBL5868616
8.14IC507.3nMCHEMBL5931935
8.10IC507.9nMCHEMBL5854554
8.05IC508.9nMCHEMBL5817049
8.03IC509.4nMCHEMBL5810667
8.00IC5010nMCHEMBL5995757
7.96IC5011nMCHEMBL5905862
7.96IC5011nMCHEMBL5898384
7.92IC5012nMCHEMBL5833422
7.92IC5012nMCHEMBL5901953
7.92IC5012nMCHEMBL5868550
7.89IC5013nMCHEMBL5846106
7.85IC5014nMCHEMBL5844164
7.82IC5015nMCHEMBL5183418
7.82IC5015nMCHEMBL5979420
7.82IC5015nMCHEMBL5985635
7.80IC5016nMCHEMBL5865458
7.80IC5016nMCHEMBL5759577
7.77IC5017nMCHEMBL5204432
7.75IC5018nMCHEMBL5948533
7.75IC5018nMCHEMBL5902271
7.72IC5019nMCHEMBL5174407
7.72IC5019nMCHEMBL5828407
7.72IC5019nMCHEMBL5977349
7.72IC5019nMCHEMBL5839974
7.70IC5020nMCHEMBL5923864
7.68IC5021nMCHEMBL5173608
7.68IC5021nMCHEMBL5801393
7.68IC5021nMCHEMBL5994208
7.66IC5022nMCHEMBL5904877
7.66IC5022nMCHEMBL5873977
7.62IC5024nMCHEMBL5866807
7.60IC5025nMCHEMBL5975004
7.60IC5025nMCHEMBL6057437
7.57IC5027nMCHEMBL5810669
7.55IC5028nMCHEMBL5776352
7.52IC5030nMCHEMBL5998629
7.50IC5032nMCHEMBL5826547
7.50IC5032nMCHEMBL5881546
7.48IC5033nMCHEMBL5772711

PubChem BioAssay actives

47 with measured affinity, of 546 total; 40 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
4-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]benzonitrile1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0065uM
3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]benzonitrile1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0150uM
4-methyl-5-[2-[4-(1H-pyrazol-5-yl)phenoxy]ethyl]-1,3-thiazole1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0170uM
N,N-dimethyl-4-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidine-1-carboxamide1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0190uM
5-[(4-fluorophenyl)methoxy]-2-(1H-pyrazol-5-yl)pyridine1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0210uM
8-imidazol-1-yl-5,6,7,8-tetrahydroquinoline2022035: Inhibition of CYP450 (unknown origin)ic500.0335uM
(3S)-N,N-dimethyl-3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidine-1-sulfonamide1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0360uM
1-[4-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidin-1-yl]ethanone1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0400uM
4-methyl-5-[2-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxy]ethyl]-1,3-thiazole1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0440uM
N-methyl-4-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidine-1-carboxamide1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0630uM
4-methyl-5-[2-[2-(1H-pyrazol-5-yl)pyrimidin-5-yl]oxyethyl]-1,3-thiazole1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0660uM
3-methylsulfonyl-5-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]phenol1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0690uM
methyl 4-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidine-1-carboxylate1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0730uM
5-[(4-methylsulfonylphenyl)methoxy]-2-(1H-pyrazol-5-yl)pyridine1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.0960uM
cyclopropyl-[4-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidin-1-yl]methanone1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.1100uM
N-[4-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]cyclohexyl]acetamide1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.1700uM
1-[(3S)-3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidin-1-yl]ethanone1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.1800uM
N-(4-chlorophenyl)-5-ethyl-N-methyl-3-phenyl-1,2-oxazole-4-carboxamide2108148: Inhibition of CYP450 (unknown origin)ic500.2512uM
5-[(3-methylsulfonylphenyl)methoxy]-2-(1H-pyrazol-5-yl)pyridine1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.2600uM
ethyl 4-[2-[4-(1H-pyrazol-5-yl)phenoxy]ethyl]piperazine-1-carboxylate1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.5100uM
5-[(1-methylsulfonylpiperidin-4-yl)methoxy]-2-(1H-pyrazol-5-yl)pyridine1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.6400uM
1-[(3R)-3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxymethyl]piperidin-1-yl]ethanone1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.6400uM
2-(dimethylamino)-2-(2-ethylphenyl)-N-[3-(3-sulfamoylphenyl)-1H-indazol-5-yl]acetamide2119433: Inhibition of CYP450 (unknown origin)ic500.7000uM
5-[[(3R)-1-methylsulfonylpiperidin-3-yl]methoxy]-2-(1H-pyrazol-5-yl)pyridine1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.7100uM
5-[[(3S)-1-methylsulfonylpiperidin-3-yl]methoxy]-2-(1H-pyrazol-5-yl)pyridine1858242: Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminescence based assayic500.7300uM
1-[4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone1216150: Inhibition of human CYP4F2 in human liver microsomes assessed as fingolimod metabolismki0.7400uM
2-[4-(trifluoromethyl)phenyl]chromen-4-one1860362: Inhibition of recombinant human CYP4F2 expressed in baculovirus-infected insect cells in presence of arachidonic acid and NADPH incubated for 15 mins by jump-dilution assay relative to controlic500.7600uM
2-pyrrolidin-1-yl-N-[3-(3-sulfamoylphenyl)-1H-indazol-5-yl]-2-thiophen-3-ylacetamide2119433: Inhibition of CYP450 (unknown origin)ic500.9000uM
4-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-N-[[(7R)-5,6,7,8-tetrahydro-1,6-naphthyridin-7-yl]methyl]cyclohexane-1,4-diamine2124397: Inhibition of CYP450 (unknown origin)ic502.5000uM
1-[3-(2,4-dimethoxyphenyl)phenyl]-2,4-dimethoxybenzene1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysisic503.7000uM
1-[(E)-2-(2,4-dimethoxyphenyl)ethenyl]-3,5-dimethoxybenzene1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysisic503.7000uM
2,4-bis(3,5-dimethoxyphenyl)pyrimidine1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysisic503.8000uM
2,5-bis(3,5-dimethoxyphenyl)thiophene1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysisic503.9000uM
[(1R,3S,3aR,5aS,5bS,6S,7aR,11aS,13aR,13bR)-1,6-dihydroxy-5a,8,8,11a,13a-pentamethyl-9-oxo-3-propan-2-yl-2,3,4,5,5b,6,7,7a,10,11,13,13b-dodecahydro-1H-cyclopenta[a]chrysen-3a-yl]methyl acetate1860381: Inhibition of recombinant CYP4F2 (unknown origin) incubated for 5 to 15 mins in presence of NADPH by LC-MS/MS analysisic504.2000uM
octadec-17-ynoic acid690542: Inhibition of leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes by UV spectroscopyic505.0000uM
4-[2-(2,4-dimethoxyphenyl)-1,3-thiazol-4-yl]phenol1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysisic505.9000uM
1-pyridin-4-yl-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalen-4-ol2022025: Inhibition of CYP450 in human liver microsomesic506.0534uM
(5R)-3-[1-(1H-indol-2-ylmethyl)piperidin-4-yl]-5-(6-methoxyquinolin-4-yl)-1,3-oxazolidin-2-one306257: Inhibition of CYP450ic507.9433uM
3-[1-[(3,4-dimethylphenyl)methyl]piperidin-4-yl]-5-(6-methoxyquinolin-4-yl)-1,3-oxazolidin-2-one306257: Inhibition of CYP450ic5010.0000uM
1-[3-(3,5-dimethoxyphenyl)phenyl]-3,5-dimethoxybenzene1973305: Inhibition of CYP450 in pooled human liver microsomes in presence of NADPH measured every 3 mins for 120 mins by fluorescence based analysisic5010.0000uM

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
Warfarinaffects response to substance, affects cotreatment, increases response to substance34
Vitamin K 1decreases metabolic processing, affects abundance, increases oxidation3
Cyclosporinedecreases expression3
Aflatoxin B1affects expression, decreases expression, increases expression3
Acenocoumarolaffects response to substance2
Benzo(a)pyrenedecreases expression2
Cisplatinaffects cotreatment, increases expression2
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amineincreases expression1
rubiarbonone Cdecreases reaction, increases hydroxylation, decreases activity1
methyleugenoldecreases expression1
propionaldehydeincreases expression1
pirinixic acidaffects binding, decreases expression, increases activity1
sulforaphaneincreases expression1
tris(1,3-dichloro-2-propyl)phosphateincreases expression1
sodium arsenitedecreases expression1
periodate-oxidized adenosineaffects expression1
menatetrenoneaffects abundance1
AICA ribonucleotideincreases expression, decreases reaction, affects reaction1
pentanalincreases expression1
19-hydroxy-5,8,11,14-eicosatetraenoic acidincreases chemical synthesis1
20-hydroxy-5,8,11,14-eicosatetraenoic acidincreases chemical synthesis1
perfluorooctane sulfonic aciddecreases expression1
fipronilaffects cotreatment, decreases expression1
perfluoro-n-nonanoic aciddecreases expression1
splitomicindecreases reaction, increases expression1
2-chloro-5-nitrobenzanilidedecreases expression, increases reaction1
STO 609decreases reaction, increases expression1
abrineincreases expression1
N-(3-chloro-4-morpholin-4-yl) phenyl-N’-hydroxyimido formamidedecreases activity1
4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrileincreases expression1

ChEMBL screening assays

223 unique, capped per target: 214 admet, 9 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL2155872BindingInhibition of leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes by UV spectroscopy2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani. — Bioorg Med Chem Lett
CHEMBL3509252ADMETEnzyme kinetics constant (Km value) for CYP4F2 was determined in human liver microsome incubated with [14C]SPP100 hemifumarateFDA drug approval package for Aliskiren hemifumarate

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 81

This page pulls from 81 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgtopdb_interactiongwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot